Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Carlisle to $43 from $44 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences reports Q1 EPS , consensus (49c)
- Castle Biosciences raises 2026 revenue view to $345M-$355M from $340M-350M
- Castle Biosciences Posts Strong Q1 Results, Raises 2026 Guidance
- Castle Biosciences price target lowered to $40 from $50 at Canaccord
- Castle Biosciences to present new data from DecisionDx-Melanoma test at AAD